3.17
price down icon5.23%   -0.175
 
loading
Schlusskurs vom Vortag:
$3.345
Offen:
$3.16
24-Stunden-Volumen:
41,347
Relative Volume:
1.74
Marktkapitalisierung:
$17.90M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.35M
KGV:
-1.0393
EPS:
-3.05
Netto-Cashflow:
$-11.88M
1W Leistung:
-8.65%
1M Leistung:
+3.26%
6M Leistung:
-25.41%
1J Leistung:
-36.22%
1-Tages-Spanne:
Value
$3.16
$3.409
1-Wochen-Bereich:
Value
$3.00
$3.57
52-Wochen-Spanne:
Value
$2.96
$11.79

Lipocine Inc Stock (LPCN) Company Profile

Name
Firmenname
Lipocine Inc
Name
Telefon
801 994 7383
Name
Adresse
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Name
Mitarbeiter
0
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
LPCN's Discussions on Twitter

Vergleichen Sie LPCN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
LPCN
Lipocine Inc
3.17 17.90M 0 -16.35M -11.88M -3.05
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.49 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
625.60 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
583.62 35.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.83 34.53B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
274.78 29.15B 3.81B -644.79M -669.77M -6.24

Lipocine Inc Stock (LPCN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2021-06-24 Eingeleitet Cantor Fitzgerald Overweight
2020-12-10 Hochstufung Ladenburg Thalmann Neutral → Buy
2018-01-12 Bestätigt H.C. Wainwright Buy
2018-01-11 Herabstufung Canaccord Genuity Buy → Hold
2017-12-08 Fortgesetzt H.C. Wainwright Buy
2016-10-07 Eingeleitet H.C. Wainwright Buy
2015-07-22 Eingeleitet ROTH Capital Buy
2015-06-23 Eingeleitet Canaccord Genuity Buy
Alle ansehen

Lipocine Inc Aktie (LPCN) Neueste Nachrichten

pulisher
Mar 30, 2025

Lipocine (NASDAQ:LPCN) Coverage Initiated by Analysts at StockNews.com - Defense World

Mar 30, 2025
pulisher
Mar 27, 2025

Lipocine’s Phase III trial of LPCN 1154 to begin for postpartum depression - Yahoo Finance

Mar 27, 2025
pulisher
Mar 26, 2025

Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154 - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

Revolutionary At-Home Postpartum Depression Drug Enters Final Testing Phase - Stock Titan

Mar 26, 2025
pulisher
Mar 22, 2025

StockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN) - Defense World

Mar 22, 2025
pulisher
Mar 21, 2025

Testosterone, TRAVERSE, And A Label Change 15 Years In The Making - News & Insights

Mar 21, 2025
pulisher
Mar 21, 2025

Lipozem Reviews (2025): Consumer Reports on Lipozem Weight Loss Formula - GlobeNewswire Inc.

Mar 21, 2025
pulisher
Mar 13, 2025

Lipocine Announces Financial Results for the Full Year Ended December 31, 2024 - Quantisnow

Mar 13, 2025
pulisher
Mar 13, 2025

Lipocine Turns Profitable: How $11.2M in Licensing Deals Transformed 2024 Results - StockTitan

Mar 13, 2025
pulisher
Mar 12, 2025

Lipocine to change FDA labeling for testosterone products -March 12, 2025 at 09:59 am EDT - Marketscreener.com

Mar 12, 2025
pulisher
Mar 12, 2025

Lipocine Announces FDA Labeling Changes for Testosterone Products - Citizentribune

Mar 12, 2025
pulisher
Mar 12, 2025

Lipocine announces FDA labeling changes for testosterone products - TipRanks

Mar 12, 2025
pulisher
Mar 12, 2025

FDA Lifts Critical Cardiovascular Warning for Testosterone Treatments: Major Win for Lipocine - StockTitan

Mar 12, 2025
pulisher
Mar 06, 2025

Lipocine (NASDAQ:LPCN) Coverage Initiated at StockNews.com - Defense World

Mar 06, 2025
pulisher
Mar 04, 2025

LPCN stock touches 52-week low at $2.92 amid market challenges By Investing.com - Investing.com South Africa

Mar 04, 2025
pulisher
Mar 04, 2025

LPCN stock touches 52-week low at $2.92 amid market challenges - Investing.com UK

Mar 04, 2025
pulisher
Mar 03, 2025

Lipocine Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView

Mar 03, 2025
pulisher
Mar 01, 2025

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024 - Marketscreener.com

Mar 01, 2025
pulisher
Feb 27, 2025

Lipocine (LPCN) Expected to Announce Earnings on Thursday - Defense World

Feb 27, 2025
pulisher
Feb 26, 2025

Lipocine (NASDAQ:LPCN) Now Covered by StockNews.com - Defense World

Feb 26, 2025
pulisher
Feb 19, 2025

Lipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.com - Armenian Reporter

Feb 19, 2025
pulisher
Feb 11, 2025

Lipocine Updates Corporate Presentation in Recent 8-K Filing - Defense World

Feb 11, 2025
pulisher
Feb 08, 2025

Lipocine (NASDAQ:LPCN) Receives Updated Regulatory Guidance for LPCN 1154 - Defense World

Feb 08, 2025
pulisher
Feb 07, 2025

Lipocine plans phase 3 study for postpartum depression drug - MSN

Feb 07, 2025
pulisher
Feb 06, 2025

Lipocine Inc. Receives Updated Regulatory Guidance on LPCN 1154 -February 06, 2025 at 09:30 am EST - Marketscreener.com

Feb 06, 2025
pulisher
Feb 06, 2025

Lipocine plans phase 3 study for postpartum depression drug By Investing.com - Investing.com South Africa

Feb 06, 2025
pulisher
Feb 06, 2025

Lipocine Receives Updated Regulatory Guidance on LPCN 1154 - The Herald Journal

Feb 06, 2025
pulisher
Feb 02, 2025

Lipocine (NASDAQ:LPCN) Earns Hold Rating from Analysts at StockNews.com - Defense World

Feb 02, 2025
pulisher
Jan 28, 2025

Postpartum Depression Market Expected to rise, 2034 | Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace, expected to drive market - Barchart

Jan 28, 2025
pulisher
Jan 20, 2025

Lipocine Updates Corporate Presentation, Files 8-K with SEC - Defense World

Jan 20, 2025
pulisher
Jan 12, 2025

(LPCN) On The My Stocks Page - Stock Traders Daily

Jan 12, 2025
pulisher
Jan 01, 2025

StockNews.com Begins Coverage on Lipocine (NASDAQ:LPCN) - Defense World

Jan 01, 2025
pulisher
Dec 19, 2024

FDA Grants Fast Track Designation to Lipocine (NASDAQ:LPCN) for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis - Defense World

Dec 19, 2024
pulisher
Dec 17, 2024

Lipocine Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits - Quantisnow

Dec 17, 2024
pulisher
Dec 17, 2024

FDA fast tracks Lipocine's sarcopenia treatment - Investing.com

Dec 17, 2024
pulisher
Dec 17, 2024

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis - PR Newswire

Dec 17, 2024
pulisher
Dec 17, 2024

FDA Grants Fast Track Designation to LPCN 1148 as Treatment for Sarcopenia - Contract Pharma

Dec 17, 2024
pulisher
Dec 11, 2024

Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference - The Eastern Progress Online

Dec 11, 2024
pulisher
Dec 11, 2024

Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session - The Eastern Progress Online

Dec 11, 2024
pulisher
Dec 11, 2024

Where are the Opportunities in (LPCN) - Stock Traders Daily

Dec 11, 2024

Finanzdaten der Lipocine Inc-Aktie (LPCN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$73.44
price up icon 2.00%
$68.32
price up icon 0.56%
$31.28
price up icon 0.35%
$20.46
price up icon 8.83%
$93.32
price up icon 3.36%
biotechnology ONC
$274.78
price up icon 1.38%
Kapitalisierung:     |  Volumen (24h):